Pediatric
Pharmaceuticals, Inc. (PPI) was formed to develop and market
unique pharmaceutical products designed to fulfill the needs
of the medical community. Its first product CAFCIT, caffeine
citrate for apnea of prematurity, received FDA approval in
September 1999 and is now on the market throughout the U.S.
PPI plans
to target the development of pharmaceuticals, many of which
will qualify as orphan drugs capable of obtaining the
financial/patent benefits of the Orphan Drug Act. Major drug
companies are usually not interested in these products because
of their relatively small sales potential. The Company also
feels that once certain specialty products are approved, they
may find a larger audience through use in other indications.
As long
term strategy, PPI plans to identify and financially support
selected university and hospital research projects that offer
strong potential as major pediatric and adult products. This
investment program should provide the Company with a stream of
new and innovative products as well as foster formal
relationships with leading medical research centers.
PPI first
became interested in thalidomide after supplying the product
for children and adults afflicted with leprosy at the Hansen's
Disease Center in Carville, LA. An analysis of existing
literature indicated the potential for the product in a number
of different areas. For the past ten years we have been
supplying investigators who have obtained an IND from the FDA.
